Oncometabolic Surgery

Summary

Recently, the concept of "Onco-metabolic surgery" has emerged, and it is a theory that if anastomosis bypassing the duodenum and upper jejunum is performed after gastrectomy in gastric cancer patients with type 2 diabetes, diabetes can be expected to improve. The authors would like to compare and analyze the effect of long bowel Luwai gastrointestinal anastomosis in gastric cancer patients with type 2 diabetes in a multicenter prospective manner with that of type 2 diabetes gastric cancer patients who underwent a conventional Luwai gastrointestinal anastomosis.

Conditions

• Gastric Cancer

Interventions

PROCEDURE

long-limb Roux-en-Y gastrojejunostomy

* Laparoscopic or robotic lower subtotal resection and extensive lymph node resection * When performing the lower gastric subtotal resection, 70% of the total gastric volume should be resected and about 30% should be left including the bottom of the stomach. * When performing Luwai-type anastomosis, the length of the biliary tract pancreatic branch, which is the field finger, is 80 centimeters, and the length of the blade finger from the stomach-factory anastomosis is 80 centimeters

Sponsors & Collaborators

• Kyungpook National University Chilgok Hospital

  collaborator OTHER

• Samsung Medical Center

  collaborator OTHER

• Asan Medical Center

  collaborator OTHER

• Seoul National University Bundang Hospital

  collaborator OTHER

• Kyung Hee University Hospital at Gangdong

  collaborator OTHER

• Kosin University Gospel Hospital

  collaborator OTHER

• Dankook University

  collaborator OTHER

• Korea University Ansan Hospital

  collaborator OTHER

• Seoul National University Hospital

  collaborator OTHER

• Gangnam Severance Hospital

  collaborator OTHER

• Keimyung University Dongsan Medical Center

  collaborator OTHER

• Wonju Severance Christian Hospital

  collaborator OTHER

• Gyeongsang National University Hospital

  collaborator OTHER

• Korea University Guro Hospital

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

20 Years

Max Age

79 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-07-07

Primary Completion

2024-05-07

Completion

2024-05-07

Countries

• South Korea

Study Locations